317 related articles for article (PubMed ID: 22098541)
21. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
[TBL] [Abstract][Full Text] [Related]
22. [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Fujishima N; Fujishima M; Inomata M; Yamanaka Y; Saitoh K; Kameoka Y; Yoshioka T; Saitoh H; Takahashi N; Hirokawa M; Sawada K
Rinsho Ketsueki; 2007 Apr; 48(4):326-31. PubMed ID: 17515125
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
24. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Mead GM; Barrans SL; Qian W; Walewski J; Radford JA; Wolf M; Clawson SM; Stenning SP; Yule CL; Jack AS; ;
Blood; 2008 Sep; 112(6):2248-60. PubMed ID: 18612102
[TBL] [Abstract][Full Text] [Related]
25. [Primary small intestinal Burkitt lymphoma treated with rituximab-combined CODOX-M/IVAC therapy without surgical resection].
Mizutani M; Umino A; Taniguchi M; Tamaki S; Tanigawa M; Tsuji K
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1229-32. PubMed ID: 24047786
[TBL] [Abstract][Full Text] [Related]
26. Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Pereira J; Bellesso M; Pracchia LF; Neto AE; Beitler B; de Almeida Macedo MC; Dias LC; Dorlhiac-Llacer PE; Dulley FL; Chamone D
Leuk Res; 2006 Jun; 30(6):681-5. PubMed ID: 16288806
[TBL] [Abstract][Full Text] [Related]
27. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
28. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
Lacasce A; Howard O; Lib S; Fisher D; Weng A; Neuberg D; Shipp M
Leuk Lymphoma; 2004 Apr; 45(4):761-7. PubMed ID: 15160953
[TBL] [Abstract][Full Text] [Related]
29. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
30. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
Wästerlid T; Brown PN; Hagberg O; Hagberg H; Pedersen LM; D'Amore F; Jerkeman M
Ann Oncol; 2013 Jul; 24(7):1879-1886. PubMed ID: 23446093
[TBL] [Abstract][Full Text] [Related]
31. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
[TBL] [Abstract][Full Text] [Related]
32. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
33. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
[TBL] [Abstract][Full Text] [Related]
34. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Moleti ML; Testi AM; Giona F; Malandruccolo L; Pescarmona E; Martino P; Paoloni F; Barberi W; Palumbo G; Mandelli F; Foa R
Leuk Lymphoma; 2007 Mar; 48(3):551-9. PubMed ID: 17454598
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
36. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Maruyama D
Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
[No Abstract] [Full Text] [Related]
38. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
[TBL] [Abstract][Full Text] [Related]
40. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M
Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
